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Marlborough, MA, United StatesEvery article I have read, and just about every conference I have
attended, in the past couple of years has proclaimed the arrival of preci-
sion medicine. ‘Precision medicine is ﬁnally here!’ This is the message
that pervades the media outlets — from online industry journals to the
NY Times — each snapping up the sound bites from genomic pioneers
bent on revolutionizing health care. This implied revolution is brought
upon by the continued advancement of next generation sequencing
technology and the associated rapid decline in the costs of sequencing
sections of a person's genome.
There is only one problemwith these assertions; they never seem to
discuss the economic reality of our healthcare system. Who is going to
ultimately pay for the precision diagnostics required to unlock precision
medicine? Health insurance companies or Medicare? Both? Unless the
clinical utility of the test has been well established, I would not count
on it. Because of this hurdle, when it comes to new test adoption, com-
mercial payers are usually the last ones to board the bus. Pharma com-
panies?Maybe. Theymight pay for a companion diagnostic if the cost of
treatment is in themany thousands of dollars. But thenwhopays for the
drug? And if a drug won't be paid for, what good is having the test? So
who does that leave? Well, you and I, the patient. And just to be clear,
whenwas the last time you rushed out to insist your doctor order an in-
formative, yet perhaps not absolutely medically necessary test that you
knew would cost you thousands of dollars?
2013 was a particularly poor year for the future of precision medi-
cine. While technology announcements that the ‘$1000 genome has
arrived’ dominated the major genomic news stories, you will have to
turn your attention to Wall Street to get the real scoop. Flip through
the earnings reports of some of the publically traded companies that
offer genetic testing and a pattern will start to emerge — signiﬁcant ﬁ-
nancial losses and statements about ‘reducedMedicare reimbursement,
Medicare non-payment, and CPT 2013’. Manygenetic testing companies
derive a signiﬁcant amount of their revenue from Medicare and com-
mercial insurance testing. Away from the headlines, the lesser-known
fact is, with the exception of certain well characterized testing with
speciﬁc Current Procedural Terminology (CPT) Molecular Pathology
(MOPATH) codes assigned — e.g. cystic ﬁbrosis and BRCA, Medicare
signiﬁcantly reduced payment for genetic testing in 2013.
So, what is CPT 2013?Medicare issues its coverage decisions annually
based on the CPT guidelines developed by the American Medical Asso-
ciation (AMA), and Medicare contractors such as Palmetto who price
these tests. In 2013, there was a restructuring of how genetic testing
is reimbursed. Prior to 2013, most laboratory developed test (LDT)E-mail address: Nabil.N.Hafez@QuestDiagnostics.com.
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specifywhich testwas being run on a sample for a speciﬁc disease, rather
it was based on the methodology of a particular assay. For example, the
following would be one way to bill for a test that screened for 23 muta-
tions in the cystic ﬁbrosis gene in 2012.
CPT 83891—Molecular diagnostics; Isolation or extraction of highly
puriﬁed nucleic acid
CPT 83892 — Molecular diagnostics; enzymatic digestion
CPT 83900—Molecular diagnostics; ampliﬁcation of patient nucleic
acid, multiplex, ﬁrst two nucleic acid sequences
CPT 83901 (×21)—Molecular diagnostics; Isolation or extraction of
highly puriﬁed nucleic acid (21 times)
CPT 83909—Molecular diagnostics; Separation and identiﬁcation by
high resolution technique (e.g., capillary electrophoresis)
CPT 83912 —Molecular diagnostics; Interpretation and report
CPT 83914 (×23)—Mutation identiﬁcation by enzymatic ligation or
primer extension, single segment (23 times for each mutation)
[2009 CPT code deﬁnitions: https://www.businessgrouphealth.org/
pub/f2f5b070-2354-d714-5166-07929500fea8.]
This process of ‘stacking’ codes was the only method labs had for
billing genetic testing. In the above test, the charges were for extracting
and digesting the DNA, amplifying it, sequencing, identifying the muta-
tions, interpreting, and reporting. You'll notice that nowhere in those
codes does it identify the genes that are being isolated and sequenced
or for which condition.
Payers have historically had limited transparency beyond the
description that some test was performed involving some molecular
diagnostic techniques on a patient sample and 23 mutations were
reported on. Whether this gene, mutations, or even the test itself
was relevant for the disease condition was anybody's guess. Deter-
mining if the test that was run on a patient had clinical utility from
this obfuscated coding mechanism was a dead end. Payers would
often reimburse for these tests without knowing what exactly they
had paid for.
Enter CPT 2013 — gone was CPT code stacking, replaced by coding
based on the number of exons sequenced or a speciﬁc CPT code for a
speciﬁc genetic disorder. CPT 2013 created a precise code for cystic
ﬁbrosis gene analysis, so the previous example of stacked codes was
simpliﬁed to this:
CPT 81220 — CFTR (cystic ﬁbrosis transmembrane conductance
regulator) (e.g.,cystic ﬁbrosis) gene analysis; common variants
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tested for and cannoweasily andquickly determine if the test ormethod-
ology for a speciﬁc condition falls under their coverage policies.
The issue for clinical labs is that very few genetic conditions have
CPT 2013 codes speciﬁcally assigned to them and new disease causing
variants for heritable conditions are discovered daily. While advances
in our knowledge of diseases and their genetic underpinnings acceler-
ates at break neck speed as sequencing costs drop, new CPT codes
based on these ﬁndings often take signiﬁcantly more time.
Most labs' test menu far exceeds the limited scope of a handful of
conditions that have assigned CPT codes — especially for labs that test
for rarer genetic disorders. Diagnostic labs have no choice except to
bill these tests for CPT 81479 — Miscellaneous molecular pathology
procedure. Now that payers have some insight into genetic tests with
deﬁned CPT codes, the chances that they would go back to paying for
miscellaneous genetic testing was close to 0%. Indeed, Medicare pay-
ment for 81479 in 2013was 0%. For the codes that are being reimbursed,
inmany cases, the new reimbursement rate associatedwith CPT 2013 is
insufﬁcient to even cover the cost of testing. This is creating ﬁnancial
pressure on many diagnostic laboratories and a number are at high
risk for bankruptcy (http://www.darkreport.com/PDF/Low-2013-
Molecular-Test-Rates-May-Bankrupt-Some-Pathology-Labs.pdf).
If you'd like to make a more informed assessment on whether
‘personalizedmedicine is here’, visit thewebsite of just about anyhealth
insurance carrier and read through the coverage policies on genetic
testing. You will quickly acquaint yourself with the phrase “Experimen-
tal or Investigational” that pervades this section for just about every
conceivable genetic test that exists. All these tests suffer from what
the payers cite is “a lack of clinical data to permit conclusions on clinical
utility and net health outcomes”.
Payer adoption of genetic testing and the reimbursement environ-
ment is lagging far behind the technology. Payers often require numer-
ous studies citing the clinical evidence of a particular diagnostic test to
appropriately assess its clinical utility before they decide to cover it for
a given condition. Take for example chromosomal microarray testing
for patients with developmental delays or autism spectrum disorders—
payers are only now starting to issue coverage for this test, a full four
years after American College of Medical Genetics (ACMG) issued a
guideline recommending it as a ﬁrst tier test for these patients (Miller
et al., 2010).
Clinicians are not without blame, they oftentimes do not take the
time to justify the medical necessity of a genetic test for a particular pa-
tient, document the clinical presentation and symptoms of the patient,
or submit the proper ICD codes. The majority of denials from payers
for even covered tests come from a lack of proper documentation by
the ordering physician.
If payers are not blazing trails towards the future of precision
medicine, then perhaps some combination of advocacy organizations,
pharmaceutical companies, and associated companion diagnostics will
get us closer. There are already a number of therapeutics that require
a genetic companion diagnostic test assaying speciﬁc gene mutations
before a doctor can prescribe the drug. Kalydeco™ is a drug developed
by Vertex Pharmaceuticals for cystic ﬁbrosis. It is only effective for the
estimated 4% of cystic ﬁbrosis patients who have a speciﬁc CF genemuta-
tion called G551D (http://www.cff.org/treatments/therapies/kalydeco/).
While Vertex does not provide the testing, they have collaborated withthe Cystic Fibrosis Foundation, which has a Mutational Analysis Program
that provides free genotyping for people with cystic ﬁbrosis.
In the near future, plummeting sequencing costs combined with
increasingly genotypically focused drug targets may pave the way for
a model where pharmaceutical companies pay for the gene or possibly
full exome sequencing of patients before they are prescribed speciﬁc
medications. This application will likely ﬁrst appear in rare disorders
and companies offering treatments for those conditions where thera-
peutics can cost hundreds of thousands of dollars annually. Paying
$1000 for a genetic test for patients en masse is not out of the question
when the return on investment in collected pharmaceutical revenue
can far exceed that initial cost. The prospect of giving pharmaceutical
companies open access to your genetic information may not be palat-
able to many people, but for those with loved ones with a debilitating
genetic disorder and mounting medical bills, this would likely not be
distasteful in the slightest.
So what does this all mean for health care and precision medicine?
There are many pretty charts that show the DNA sequencing cost curve
compared toMoore's law. However, unless the healthcare industry is re-
lying on patients ponying up thousands of dollars to have their genomes
sequenced, I am afraidwe are farther fromwhen genetic testingwill be a
routine part of healthcare thanmost of us suspected, or would like. Right
now, personalized medicine could be here for those willing to shell out
for it. For the rest of us, the genetic revolution has been delayed while
policy catches up with technology.
This gloomy outlook does not howevermean that genetic testinghas
no future inmedicine, quite the contrary. There are signiﬁcant examples
of how it can dramatically impact patient care. A child with a certain
type of epilepsy exhibiting daily multiple seizures could be effectively
diagnosed and treated. A genetic test could indicate that the child
has a mutation in the SLC2A1 gene which codes a protein that moves
glucose in and out of the brain. Treating the child with a high-fat
ketogenic diet can almost immediately stop the seizures (http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC3152152/). Thus, genetic
testing can be a powerful tool in a clinician's arsenal when utilized
appropriately. However there is much education and major policy
work that needs to take place before it becomes widely accessible.
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